Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Immune Pharmaceuticals Inc. Snapshot | 6 | 1 |
| Immune Pharmaceuticals Inc. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Immune Pharmaceuticals Inc. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Immune Pharmaceuticals Inc. Pipeline Review | 10 | 5 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Combination Treatment Modalities | 12 | 1 |
| Pipeline Products Partnered Products | 13 | 1 |
| Partnered Products/Combination Treatment Modalities | 14 | 1 |
| Immune Pharmaceuticals Inc. Pipeline Products Glance | 15 | 5 |
| Immune Pharmaceuticals Inc. Late Stage Pipeline Products | 15 | 1 |
| Phase III Products/Combination Treatment Modalities | 15 | 1 |
| Immune Pharmaceuticals Inc. Clinical Stage Pipeline Products | 16 | 1 |
| Phase II Products/Combination Treatment Modalities | 16 | 1 |
| Phase I Products/Combination Treatment Modalities | 17 | 1 |
| Immune Pharmaceuticals Inc. Early Stage Pipeline Products | 18 | 1 |
| IND/CTA Filed Products/Combination Treatment Modalities | 18 | 1 |
| Preclinical Products/Combination Treatment Modalities | 19 | 1 |
| Immune Pharmaceuticals Inc. Drug Profiles | 20 | 22 |
| histamine dihydrochloride | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 3 |
| (amitriptyline + ketamine hydrochloride) | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 2 |
| bertilimumab | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 2 |
| crolibulin | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 2 |
| lidocaine hydrochloride | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| F-573 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| cyclosporine | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| Ferritizumab | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| Monoclonal Antibodies to Target HLA-DR and CD5 for Leukemia | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Monoclonal Antibody Conjugate to Target EGFR for Non-Small Cell Lung Cancer | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| Monoclonal Antibody Conjugate to Target HER2 for Metastatic Prostate Cancer | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Monoclonal Antibody Conjugate to Target HER3 for Solid Tumors | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| verubulin | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 3 |
| Immune Pharmaceuticals Inc. Pipeline Analysis | 42 | 6 |
| Immune Pharmaceuticals Inc. Pipeline Products by Target | 42 | 2 |
| Immune Pharmaceuticals Inc. Pipeline Products by Route of Administration | 44 | 1 |
| Immune Pharmaceuticals Inc. Pipeline Products by Molecule Type | 45 | 1 |
| Immune Pharmaceuticals Inc. Pipeline Products by Mechanism of Action | 46 | 2 |
| Immune Pharmaceuticals Inc. Recent Pipeline Updates | 48 | 9 |
| Immune Pharmaceuticals Inc. Dormant Projects | 57 | 1 |
| Immune Pharmaceuticals Inc. Discontinued Pipeline Products | 58 | 1 |
| Discontinued Pipeline Product Profiles | 58 | 1 |
| histamine dihydrochloride | 58 | 1 |
| verubulin | 58 | 1 |
| Immune Pharmaceuticals Inc. Locations And Subsidiaries | 59 | 1 |
| Head Office | 59 | 1 |
| Other Locations &Subsidiaries | 59 | 1 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |